Rein Therapeutics (RNTX) Profit After Tax (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Profit After Tax of -$18000.0 for Q4 2025, up 99.96% year-over-year from -$9002.0 in Q4 2024, and up 99.68% quarter-over-quarter from -$5.6 million in Q3 2025.
Rein Therapeutics (RNTX) Profit After Tax (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Profit After Tax for 10 consecutive years, with -$18000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Profit After Tax rose 99.96% year-over-year to -$18000.0; the TTM figure through Mar 2026 stood at -$12.4 million (up 77.72% YoY), while the FY2025 annual figure was -$44000.0, up 99.93% from the prior year.
- Profit After Tax advanced to -$18000.0 in Q4 2025 per RNTX's latest filing, from -$5.6 million in the prior quarter.
- Across five years, Profit After Tax topped out at $19.4 million in Q4 2021 and bottomed at -$40.9 million in Q4 2024.
- Historically, Profit After Tax has averaged -$6.3 million across 5 years, with a median of -$5.8 million in 2021.
- Annual changes were most pronounced in 2021 — Profit After Tax soared 492.5% — and 2024, when it tumbled 292650.0%.
- Rein Therapeutics' Profit After Tax stood at $19.4 million in 2021, then slumped by 240.95% to -$27.3 million in 2022, then surged by 99.77% to -$63000.0 in 2023, then tumbled by 64877.78% to -$40.9 million in 2024, then soared by 99.96% to -$18000.0 in 2025.
- Business Quant data shows RNTX's Profit After Tax at -$18000.0 in Q4 2025, -$5.6 million in Q3 2025, and -$6.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | -6.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.38 Mn |
| Mar 31, 2026 | -5.84 Mn |
| Dec 31, 2025 | -18,000.00 |
| Sep 30, 2025 | -5.58 Mn |
| Jun 30, 2025 | -6.82 Mn |
| Mar 31, 2025 | -14,000.00 |
| Dec 31, 2024 | -40.94 Mn |
| Sep 30, 2024 | -5.85 Mn |
| Jun 30, 2024 | -8.94 Mn |
| Mar 31, 2024 | -7.11 Mn |
| Dec 31, 2023 | -63,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Jun 30, 2023 | -1.79 Mn |
| Mar 31, 2023 | -4.78 Mn |
| Dec 31, 2022 | -27.28 Mn |
| Sep 30, 2022 | -6.37 Mn |
| Jun 30, 2022 | -7.99 Mn |
| Mar 31, 2022 | -8.42 Mn |
| Dec 31, 2021 | 19.35 Mn |
| Sep 30, 2021 | -5,000.00 |